Is Saakshi Medtech overvalued or undervalued?

As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors.
The company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment.